Search Results
Your search for ,dUe matches 5553 pages
Showing 5351 - 5400New Test Developed to Detect Men at High Risk of Prostate Cancer Recurrence
A new genetic signature to identify prostate cancer patients who are at high risk of their cancer recurring after surgery or radiotherapy has been developed by researchers in Canada, according to a study presented at the 33rd Conference of the European Society for Radiotherapy and Oncology in...
HLA Class I Antigen Expression Predicts Overall Survival Benefit With Aspirin Use in Colon Cancer
In a cohort study reported in JAMA Internal Medicine, Reimers et al found that aspirin use was associated with a significant 47% reduction in mortality risk after diagnosis of colon cancer expressing HLA class I antigen. There was no difference in aspirin benefit according to strong or weak...
Findings of AURELIA Trial Support Consideration of Bevacizumab/Chemotherapy in Carefully Selected Patients With Platinum-Resistant Ovarian Cancer
The recently reported open-label phase III AURELIA trial showed that the addition of bevacizumab (Avastin) to chemotherapy resulted in significant improvements in progression-free survival, the primary study endpoint, and objective response rate in women with recurrent platinum-resistant ovarian...
Adding Bevacizumab to Chemotherapy Improves Progression-Free Survival in Platinum-Resistant Recurrent Ovarian Cancer
Single-agent chemotherapy is standard in platinum-resistant ovarian cancer. In the open-label phase III AURELIA trial reported in the Journal of Clinical Oncology, Pujade-Lauraine et al found that the addition of bevacizumab (Avastin) to chemotherapy resulted in significant improvement in...
Radiofrequency Ablation Reduces Risk of High-Grade Dysplasia and Adenocarcinoma vs Endoscopic Surveillance in Patients With Barrett’s Esophagus
Barrett’s esophagus with low-grade dysplasia increases risk of esophageal adenocarcinoma. In a European study reported in JAMA, Phoa et al assessed whether endoscopic radiofrequency ablation reduced the rate of neoplastic progression compared with endoscopic surveillance in patients with...
Phase II Trial Shows Feasibility of Customized Adjuvant Treatment in NSCLC, but Phase III Trial Canceled Due to Unreliability of ERCC1 Readouts
In the phase II Tailored Postsurgical Therapy in Early-Stage NSCLC (TASTE) trial (IFCT-0801), reported in the Journal of Clinical Oncology, Wislez et al examined the feasibility of customized adjuvant treatment based on EGFR mutation status and expression of ERCC1 (excision repair...
Ceritinib Highly Active in Patients With ALK-Rearranged Advanced NSCLC, Including Those With Prior Crizotinib Treatment
Non–small cell lung cancer (NSCLC) harboring ALK rearrangement is sensitive to the ALK inhibitor crizotinib (Xalkori), but resistance ultimately occurs. In a phase I study reported in The New England Journal of Medicine, Shaw et al found that the more-potent ALK inhibitor ceritinib was...
Long-Term Benefit With Dasatinib After Imatinib Failure in Chronic-Phase CML
Patients with chronic myeloid leukemia (CML) in the chronic phase who are resistant or intolerant to imatinib (Gleevec) can experience long-term benefit with dasatinib (Sprycel), according to results of a randomized phase III study. The CA180-034 study also found that early molecular and...
Prolonged Administration of Azacitidine Improves Response in Myelodysplasia, Less So in Combination With Entinostat
In the phase II US Leukemia Intergroup Trial E1905 reported in the Journal of Clinical Oncology, Prebet et al found that prolonged administration of lower-dose azacitidine produced a high response rate in patients with myelodysplastic syndrome or acute myeloid leukemia (AML) with myelodysplastic...
Erlotinib and Gefitinib Offer Similar Benefit in EGFR-Mutated Non–Small Cell Lung Cancer
A retrospective study has shown that two targeted therapy drugs—erlotinib (Tarceva) and gefitinib (Iressa)—achieved similar outcomes among people with metastatic or recurrent non–small cell lung cancer (NSCLC) harboring an EGFR mutation. These EGFR tyrosine kinase inhibitors have...
Phase II Study Suggests Benefit of Adding Rituximab to Chlorambucil in First-Line Treatment for Chronic Lymphocytic Leukemia
In a UK phase II study reported in the Journal of Clinical Oncology, Hillmen et al assessed the safety and activity of adding rituximab (Rituxan) to chlorambucil (Leukeran) in first-line treatment of chronic lymphocytic leukemia (CLL). Such a regimen may be an alternative to fludarabine-based...
Long-Term Follow-up Shows Surgery Plus Radiation Offers Mixed Results in Soft-Tissue Sarcoma
Adjuvant radiation following surgery for soft-tissue sarcoma of the extremities did not lead to a survival benefit and seemed to be associated with some degree of long-term limb complications, according to a presentation at the 2014 Society of Surgical Oncology (SSO) Cancer Symposium in Phoenix...
Stool Multitarget DNA Test More Sensitive, But Less Specific Than Fecal Immunochemical Test for Colorectal Cancer Screening in Persons at Average Risk
In a study reported in The New England Journal of Medicine, Imperiale et al found that a noninvasive, multitarget stool DNA test—including assays for KRAS mutations, aberrant NDRG4 and BMP3 methylation, β-actin, and hemoglobin—was significantly more sensitive but significantly less ...
Harms Outweigh Benefits for Women Aged 70 and Over in National Breast Cancer Screening Programs
Extending national breast cancer screening programs to women over the age of 70 does not result in a decrease in the number of cancers detected at advanced stages, according to new research from The Netherlands. Instead, researchers told attendees at the 9th European Breast Cancer Conference that...
Preclinical Study Suggests Benefits of Increased Tumor Perfusion and Reduced Tumor Hypoxia With Exercise in Prostate Cancer
In a study reported in the Journal of the National Cancer Institute, McCullough et al used an orthotopic rat model of prostate cancer to assess the effects of exercise on tumor hemodynamics and tissue hypoxia. Their findings of enhanced tumor perfusion and diminished tumor hypoxia suggest that...
Regular Physical Activity Reduces Breast Cancer Risk Irrespective of Age or Weight
Participating in athletic activities for more than an hour a day reduces the risk of breast cancer, and this applies to women of any age and any weight, regardless of geographic location, according to research presented at the 9th European Breast Cancer Conference in Glasgow. Compared with the...
Health Gap Between Adult Survivors of Childhood Cancer and Siblings Widens With Age
Adult survivors of childhood cancer face significant health problems as they age and are five times more likely than their siblings to develop new cancers, heart disease, and other serious health conditions beyond the age of 35, according to the latest findings from the Childhood Cancer Survivor...
Shortening of Leukocyte Telomeres Associated With Increased All-Cause and Breast Cancer–Specific Mortality in Breast Cancer Patients
Short telomeres are associated with increased risk of cancer, but data on telomere length and mortality in breast cancer survivors are inconsistent. In a study reported in the Journal of the National Cancer Institute, Duggan et al found that decreases in telomere length between baseline and 30...
ASCO Urges Raising the Bar for Cancer Clinical Trials
The American Society of Clinical Oncology is calling on cancer researchers, clinical trial sponsors, and drug developers to employ clinical trial designs that aim to significantly extend the lives of people with cancer. In a Special Article published in the Journal of Clinical Oncology, Ellis...
Report Shows More Screening Has Led to a 30% Drop in Colon Cancer Rates
Findings from a report by Siegel et al of the American Cancer Society (ACS) show that the rate at which people are diagnosed with colorectal cancer in the United States has dropped by 30% in the last 10 years among people aged 50 years and older. The researchers say the decline in incidence is due...
No Overall Survival Benefit of First-Line Doxorubicin Plus Ifosfamide vs Doxorubicin Alone in Advanced Soft-Tissue Sarcoma
In the open-label, phase III EORTC 62012 trial reported in The Lancet Oncology, Judson et al found that doxorubicin plus ifosfamide was not associated with any overall survival advantage compared with doxorubicin alone in patients with advanced or metastatic soft-tissue sarcoma. Progression-free...
Rituximab Maintenance Delays Need for Subsequent Treatment vs Watchful Waiting in Asymptomatic Nonbulky Follicular Lymphoma
In an open-label phase III trial reported by Ardeshna et al in The Lancet Oncology, rituximab (Rituxan) induction plus maintenance was found to delay the need for subsequent therapy and improve elements of quality of life vs watchful waiting in patients with advanced asymptomatic nonbulky...
First Comprehensive Report on U.S. Cancer Care Finds Patient Access Threatened by Growing Demand, Physician Shortages
The first-ever comprehensive assessment of challenges facing the U.S. cancer care system suggests that patient access to cancer care will be threatened as growing demand for care outstrips the supply of oncologists, and as cost pressures force the closure of small physician practices that form the...
Fertility Concerns Affect Treatment Choices in Young Women With Breast Cancer, but Few Use Preservation Options
Little is known about how fertility concerns affect treatment decisions or fertility preservation strategies at the time of initial diagnosis of breast cancer. In an ongoing multicohort study reported in the Journal of Clinical Oncology, Ruddy et al found that most young women with breast cancer...
No Benefit of Early Zoledronic Acid in Reducing Skeletal-Related Events in Castration-Sensitive Prostate Cancer With Bone Metastases
As reported in the Journal of Clinical Oncology by Smith et al, the double-blind phase III Cancer and Leukemia Group B (CALGB) 9020/Alliance trial assessed the effect of early initiation of zoledronic acid in reducing risk of skeletal-related events in men with castration-sensitive prostate cancer. ...
Same Progression-Free Survival, Better Quality of Life With Lower-Dose Weekly vs Every-3-Week Carboplatin/Paclitaxel in Advanced Ovarian Cancer
In an open-label phase III trial (MITO-7) reported in The Lancet Oncology, Pignata et al found that while a lower-dose weekly carboplatin/paclitaxel regimen did not improve progression-free survival compared with standard every-3-week carboplatin/paclitaxel as first-line treatment of advanced...
‘Real World’ Safety Study of Vemurafenib in BRAF V600–Mutated Metastatic Melanoma Shows Similar Safety Profile as Pivotal Trials
As reported in The Lancet Oncology by Larkin et al, interim results of a safety study designed to reflect the spectrum of patients encountered in routine practice suggest that vemurafenib (Zelboraf) has a safety profile in patients with BRAF V600–mutated metastatic melanoma similar to that...
Intensity-Modulated Radiation Therapy Reduces PEG Tube Dependence and Severe Skin and Mucous Membrane Toxicity in Oropharyngeal Cancer
In a single-center experience reported in JAMA Otolaryngology-Head & Neck Surgery, Lohia et al found that intensity-modulated radiation therapy for oropharyngeal cancer reduces percutaneous endoscopic gastrostomy (PEG) tube dependence and severe skin and mucous membrane toxicity compared with...
CAR T-Cell Therapy Yields Promising Complete Response Rates in Patients With Relapsed/Refractory B-Cell ALL
In a recent study published in Science Translational Medicine, Davila et al found that 88% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) who were treated with genetically modified versions of their own immune cells achieved overall complete response. Most...
Adding Bevacizumab to Chemotherapy Improves Survival in Advanced Cervical Cancer
Retreatment with cisplatin has reduced effectiveness in patients with recurrent cervical cancer who have received cisplatin with radiation therapy. In a 2×2 factorial phase III trial reported in The New England Journal of Medicine, Tewari et al compared cisplatin/paclitaxel vs nonplatinum...
Use of Intravenous Pegaspargase in Adapted Pediatric Regimen Is Feasible in Adults With Newly Diagnosed ALL
Asparaginase treatment, standard in pediatric acute lymphoblastic leukemia (ALL) regimens, is excluded or used for shorter durations in treatment of adults with ALL due to risk of toxicity. In a study reported in Journal of Clinical Oncology, Douer et al evaluated a pegaspargase (Oncaspar) dosing...
No Mortality Benefit of Mammography Screening in 25-Year Follow-up of Canadian National Breast Screening Study
As reported in BMJ by Miller et al, the 25-year follow-up of the Canadian National Breast Screening Study has shown no mortality benefit of annual mammography screening for breast cancer compared with physical examination or usual care. Mammography screening was associated with...
Extended Follow-up in BRIM-3 Shows Prolonged Survival With Vemurafenib in BRAF V600E/K Mutation–Positive Melanoma
In the BRIM-3 trial, vemurafenib (Zelboraf) was associated with improved progression-free and overall survival vs dacarbazine in patients with advanced BRAF V600 mutation–positive melanoma. In an extended follow-up reported in The Lancet Oncology, McArthur et al found that superior survival...
Antifungal Itraconazole Shows Activity in Basal Cell Carcinoma
In an open-label exploratory phase II trial reported in the Journal of Clinical Oncology, Kim et al found that the antifungal agent itraconazole, which inhibits the Hedgehog signaling pathway, reduced tumor cell proliferation, Hedgehog pathway activity, and tumor area in patients with basal cell...
Novel Photon-Counting Technique Increases Detection Rate in Screening Mammography
As mammography screening has shifted to digital technology, a range of computed radiography and direct radiography systems have emerged. Digital mammography screening with a new photon-counting technique offers high diagnostic performance, according to a study reported by Weigel et al in Radiology. ...
MicroRNA-181a Shows Promise as a Biomarker for Late-Stage Ovarian Cancer
In patients with late-stage epithelial ovarian cancer, high levels of microRNA-181a may be predictive of chemotherapy resistance and disease progression, according to the results of a study reported by Parikh et al in Nature Communications. Thus, microRNA-181a may serve as a biomarker for prognosis ...
Obesity Linked to Poor Survival in Patients With Tongue Cancer
Cancer experts from Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College are collaborating to understand the link between obesity and cancer. Most recently, their research has yielded an interesting association: Obesity prior to diagnosis is associated with a fivefold increase...
Hyaluronan Synthase 3 Variant Associated With Increased Risk of Anthracycline-Related Cardiomyopathy
In a study reported in the Journal of Clinical Oncology, Wang et al in the Children’s Oncology Group identified a common single nucleotide polymorphism, rs2232228, in the hyaluronan synthase 3 (HAS3) gene that is associated with anthracycline dose–related risk of cardiomyopathy in...
Improved Survival With Four-Drug Induction Regimen Followed by Maintenance in Initial Treatment of Transplant-Ineligible Multiple Myeloma
In an updated analysis of an Italian phase III trial reported in the Journal of Clinical Oncology, Palumbo et al found that induction with bortezomib (Velcade), melphalan, prednisone, and thalidomide (Thalomid) followed by bortezomib plus thalidomide maintenance (VMPT-VT) significantly improved...
Enzalutamide Improves Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Enzalutamide (Xtandi) improved survival by 29% in men with chemotherapy-naive metastatic castration-resistant prostate cancer and reduced the risk of radiographic progression by 81%, according to complete results of the randomized, double-blind, placebo-controlled, multinational, phase III PREVAIL...
Good Results With Telephone Genetic Counseling for Breast and Ovarian Cancer
As genomic testing becomes more common, genetic counseling is increasingly performed via telephone. BRCA1/2 mutation carries increased risk for breast and ovarian cancer. In a noninferiority study reported in the Journal of Clinical Oncology, Schwartz et al compared genetic counseling for BRCA1/2...
Telephone-Based Intervention Improves Colorectal Cancer Screening in At-Risk Relatives of Patients With Colorectal Cancer
Individuals at increased familial risk of colorectal cancer have poor adherence to colonoscopy screening recommendations, especially those in rural and other geographically underserved populations. In a study (Family CARE trial) reported in the Journal of Clinical Oncology, Kinney et al found that...
PI3K-Delta Inhibitor Idelalisib Produces High Response Rates in Relapsed Indolent Lymphoma
Phosphatidylinositol 3-kinase (PI3K)-delta mediates B-cell receptor signaling and microenvironment support signals that promote the growth and survival of malignant B lymphocytes. In a phase II study reported in The New England Journal of Medicine, Gopal et al found that the PI3K-delta inhibitor...
Adding Idelalisib to Rituximab Improves Progression-Free and Overall Survival in Patients With Difficult-to-Treat, Relapsed CLL
Use of standard chemotherapy is difficult in patients with relapsed chronic lymphocytic leukemia (CLL) who have significant coexisting medical conditions. In a phase III trial reported in The New England Journal of Medicine, Furman et al found that the combination of idelalisib, an oral inhibitor...
No Survival Benefit of Adjuvant 5-FU–Based Chemotherapy After Neoadjuvant Radiotherapy or Chemoradiation for Resectable Rectal Cancer
As reported in The Lancet Oncology by Bosset et al, long-term results of the European Organisaton for Research and Treatment of Cancer (EORTC) trial 22921 indicate that adjuvant fluorouracil (5-FU)-based chemotherapy after preoperative radiotherapy with or without chemotherapy does not affect...
Intensity-Modulated Radiation Therapy Improves Survival in Patients With Head and Neck Cancer
Patients with cancers of the head and neck who received intensity-modulated radiation therapy experienced improved outcomes, as well as reduced toxicities, compared to patients receiving conventional radiation therapy, according to findings published online in Cancer by Beadle et al. The study is...
Afatinib Improves Progression-Free Survival vs Cisplatin/Gemcitabine in First-Line Treatment of Asian Patients With Advanced EGFR-Mutant NSCLC
Afatinib (Gilotrif) improves progression-free survival compared with pemetrexed (Alimta)/cisplatin in first-line treatment of patients with EGFR mutation–positive advanced non–small cell lung cancer (NSCLC). In the phase III LUX-Lung 6 trial reported in The Lancet Oncology, Wu ...
Pilot Study Shows Promise of Neoadjuvant Chemotherapy Without Routine Radiotherapy in Patients With Locally Advanced Rectal Cancer
Neoadjuvant chemoradiotherapy delays administration of optimal chemotherapy in stage II to III rectal cancer. In a pilot study reported in the Journal of Clinical Oncology, Schrag et al assessed outcomes with neoadjuvant FOLFOX (fluorouracil, leucovorin, oxaliplatin)/bevacizumab (Avastin) with...
Addition of Nintedanib to Docetaxel Improves Progression-Free Survival as Second-Line Treatment in NSCLC
In a phase III trial (LUME-Lung 1) reported in The Lancet Oncology, Reck et al assessed the addition of nintedanib to docetaxel in second-line treatment of non–small cell lung cancer (NSCLC). The combination significantly improved progression-free survival in all patients and improved overall ...
High Prevalence of Platinum-Related Hearing Loss in Children With High-Risk Neuroblastoma, With Differences According to Audiometry Scales
The reported prevalence of platinum-associated ototoxicity in children with high-risk neuroblastoma varies widely due to small patient samples and use of disparate grading scales. In a study reported in the Journal of Clinical Oncology, Landier et al in the Children’s Oncology Group assessed...
